{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:49:22Z","timestamp":1791679762816,"version":"4.3.4"},"reference-count":43,"publisher":"SAABRON PRESS","issue":"2","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.46989\/001c.160121","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:49:46Z","timestamp":1778593786000},"source":"Crossref","is-referenced-by-count":0,"title":["Is Pseudo-progression post-CAR T therapy real?"],"prefix":"10.46989","volume":"8","author":[{"given":"Alicia","family":"Shin","sequence":"first","affiliation":[{"name":"University of California, Los Angeles, CA 90024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian","family":"Rahbari","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichai","family":"Chinratanalab","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA"},{"name":"Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA"},{"name":"Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetola","family":"Kassim","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA"},{"name":"Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jerkins","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA"},{"name":"Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA"},{"name":"Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Orton","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Gilmore","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Shultes","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Sawyer","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salyka","family":"Sengsayadeth","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA"},{"name":"Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan","family":"Oluwole","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA"},{"name":"Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5182-3870","authenticated-orcid":true,"given":"Tae Kon","family":"Kim","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"},{"name":"Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA"},{"name":"Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN 37232, USA"},{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"F. S., et al. Hodi","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements","volume":"19","author":"M., et al. Nishino","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"L., et al. Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"6935","DOI":"10.1182\/blood-2023-189047","article-title":"Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy","volume":"142","author":"T., et al. Schroeder","year":"2023","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41409-020-01156-y","article-title":"Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma","volume":"56","author":"I., et al. Danylesko","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2020.11.7.6","article-title":"Pseudoprogression and Immunotherapy Phenomena","volume":"11","author":"S. Waxman","year":"2020","journal-title":"JADPRO"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jtho.2017.09.001","article-title":"Pseudoprogression Associated with Clinical Deterioration and Worsening Quality of Life in Malignant Pleural Mesothelioma","volume":"13","author":"M. B. Barnet","year":"2018","journal-title":"J Thorac Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/neuonc\/nou129","article-title":"Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence","volume":"17","author":"A., et al. Radbruch","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"7625","DOI":"10.21037\/jtd-2025-1381","article-title":"Continuing immune checkpoint inhibitors after pseudoprogression improves survival in lung cancer patients: a systematic review and meta-analysis","volume":"17","author":"A., et al. Huang","year":"2025","journal-title":"J Thorac Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab","volume":"34","author":"F. S., et al. Hodi","year":"2016","journal-title":"JCO"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"D. J. Baker","year":"2023","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/j.jtho.2018.05.008","article-title":"CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC","volume":"13","author":"P., et al. Rocha","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.lungcan.2017.08.020","article-title":"Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy","volume":"113","author":"M. J. Hochmair","year":"2017","journal-title":"Lung Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lungcan.2016.10.014","article-title":"Report of two cases of pseudoprogression in patients with non\u2013small cell lung cancer treated with nivolumab\u2014including histological analysis of one case after tumor regression","volume":"102","author":"J., et al. Tanizaki","year":"2016","journal-title":"Lung Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"C. J., et al. Turtle","year":"2016","journal-title":"Journal of Clinical Investigation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cpt.2561","article-title":"In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed\/Refractory Large B-Cell Lymphoma","volume":"112","author":"K., et al. Ogasawara","year":"2022","journal-title":"Clin Pharma and Therapeutics"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"797440","DOI":"10.3389\/fbioe.2022.797440","article-title":"Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions","volume":"10","author":"A., et al. Alnefaie","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"M., et al. Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"D. C. Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"A., et al. Shimabukuro-Vornhagen","year":"2018","journal-title":"j. immunotherapy cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights","volume":"130","author":"A. E., et al. Obstfeld","year":"2017","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ejh.14076","article-title":"CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?","volume":"112","author":"A. N. Khan","year":"2024","journal-title":"European J of Haematology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"E. C. Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fimmu.2020.00702","article-title":"Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward","volume":"11","author":"L. Jafarzadeh","year":"2020","journal-title":"Front. Immunol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"A. D. McLellan","year":"2019","journal-title":"Immunol Cell Biol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"K. M., et al. Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"J. J., et al. Melenhorst","year":"2022","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total Costs of Chimeric Antigen Receptor T - Cell Immunotherapy","volume":"4","author":"I. Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma","volume":"25","author":"J., et al. Wang","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/imt-2020-0188","article-title":"Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy","volume":"13","author":"J. Huang","year":"2021","journal-title":"Immunotherapy"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1007\/s00259-022-05722-y","article-title":"Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion","volume":"49","author":"D. Cohen","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/10428194.2022.2161304","article-title":"Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas","volume":"64","author":"C., et al. Sortais","year":"2023","journal-title":"Leukemia & Lymphoma"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"S. T. Bhaskar","year":"2024","journal-title":"Clinical Hematology International"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1182\/blood-2023-185520","article-title":"Early Progressions of Undetermined Significance (EPUS) in the Month Following CAR-T Cells for B-Cell NHL Is Mainly Related to Pseudoprogression","volume":"142","author":"B., et al. Tisserand","year":"2023","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"M. J., et al. Frank","year":"2024","journal-title":"The Lancet"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1504104","DOI":"10.3389\/fimmu.2024.1504104","article-title":"Pseudoprogression in CAR-T cell therapy for solid tumor: Case report","volume":"15","author":"X., et al. Zhao","year":"2024","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcag037","article-title":"Pseudoprogression after CAR T-cell therapy mimicking orbital lymphoma relapse","author":"T. Miyachi","year":"2026","journal-title":"QJM hcag037"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"S. Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.46989\/001c.116261","article-title":"The Evolving Role of Bridging Therapy during CAR-T Therapy","volume":"6","author":"S. T. Bhaskar","journal-title":"Clin Hematol Int"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40259-020-00425-y","article-title":"Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy","volume":"34","author":"M. Frelaut","year":"2020","journal-title":"BioDrugs"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1\/PD-L1","volume":"23","author":"S., et al. Champiat","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases","volume":"58","author":"A. M., et al. Di Giacomo","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria","volume":"15","author":"J. D., et al. Wolchok","year":"2009","journal-title":"Clinical Cancer Research"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/160121-is-pseudo-progression-post-car-t-therapy-real","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:43:57Z","timestamp":1791679437000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/160121-is-pseudo-progression-post-car-t-therapy-real"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.160121","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}